secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001628280-22-006887
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci posts Q4 revenue $1.5M, net loss $25.2M; reveals AI antibody design breakthroughs, partners NVIDIA
--------------------------------------------------------------------------------

- Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.
- Cash of $279.9M; expects ~$120M net cash burn in 2022 (incl. ~$10.5M restricted cash).
- Announced ML models predicting antibody affinity across 4 orders of magnitude and naturalness scoring.
- Formed research collaboration with NVIDIA to scale in-silico drug discovery on A100 GPUs.
- Entered Merck collaboration for Bionic Enzyme; projected 8 active programs in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/0001628280-22-006887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/absc-20220322.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-006887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer